Handelsbanken Fonder AB Has $5.34 Million Stake in Insulet Co. (NASDAQ:PODD)

Handelsbanken Fonder AB grew its holdings in shares of Insulet Co. (NASDAQ:PODD - Free Report) by 7.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,316 shares of the medical instruments supplier's stock after purchasing an additional 1,400 shares during the period. Handelsbanken Fonder AB's holdings in Insulet were worth $5,335,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet in the 4th quarter valued at $36,000. Itau Unibanco Holding S.A. acquired a new position in Insulet in the 4th quarter valued at $42,000. SRS Capital Advisors Inc. lifted its position in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 56 shares during the period. Assetmark Inc. boosted its holdings in Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after purchasing an additional 246 shares in the last quarter. Finally, Coppell Advisory Solutions LLC increased its position in Insulet by 135.0% during the 4th quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock worth $74,000 after purchasing an additional 162 shares during the period.

Insulet Stock Up 0.3%

Shares of NASDAQ PODD traded up $1.01 during trading on Friday, reaching $304.63. 670,638 shares of the stock were exchanged, compared to its average volume of 710,826. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. The business's 50-day moving average price is $286.00 and its 200 day moving average price is $274.69. The company has a market capitalization of $21.44 billion, a price-to-earnings ratio of 52.61, a price-to-earnings-growth ratio of 3.62 and a beta of 1.37. Insulet Co. has a twelve month low of $173.00 and a twelve month high of $329.33.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $569.00 million during the quarter, compared to analyst estimates of $543.20 million. During the same quarter last year, the firm earned $0.73 EPS. Insulet's quarterly revenue was up 28.8% on a year-over-year basis. As a group, equities analysts forecast that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analysts Set New Price Targets

PODD has been the topic of several research analyst reports. Oppenheimer boosted their price target on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Wells Fargo & Company set a $322.00 price objective on Insulet in a research report on Monday, April 28th. Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a research note on Friday, May 30th. Piper Sandler raised their price target on shares of Insulet from $285.00 to $310.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Finally, Wolfe Research raised shares of Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective for the company in a research report on Tuesday, May 13th. Three equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $318.41.

Insider Buying and Selling

In other Insulet news, SVP John W. Kapples sold 5,278 shares of Insulet stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now owns 23,180 shares of the company's stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now owns 3,231 shares in the company, valued at approximately $888,525. This trade represents a 36.10% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company's stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.